A Phase 1b/2, Open-Label, Multicenter, Dose Escalation And Dose Expansion Study Of Nktr-255 In Combination With Cetuximab As A Salvage Regimen For Solid Tumors
|Effective start/end date||11/30/20 → 11/30/25|
- NEKTAR THERAPEUTICS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.